Metastatic Breast Cancer Clinical Trials in San Antonio, Texas

8 studies are recruiting for metastatic breast cancer in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

   This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination with BNT327 (also known as pumitamig and PM8002) in participants with hor…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, Texas

   Locations

   79 in total

   Run by

   BioNTech SE

   See if you can join NCT06827236 on ClinicalTrials.gov

2. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

   This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Next Oncology, San Antonio, Texas

   Locations

   62 in total

   Run by

   BeOne Medicines

   See if you can join NCT06120283 on ClinicalTrials.gov

3. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

   First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas San Antonio (UTSA), San Antonio, Texas

   Locations

   44 in total

   Run by

   TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

   See if you can join NCT06625775 on ClinicalTrials.gov

4. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

   This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Texas Oncology-San Antonio Cancer Care, San Antonio, Texas

   Locations

   79 in total

   Run by

   BriaCell Therapeutics Corporation

   See if you can join NCT06072612 on ClinicalTrials.gov

5. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

   This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Trial Site, San Antonio, Texas

   Locations

   181 in total

   Run by

   Olema Pharmaceuticals, Inc.

   See if you can join NCT07085767 on ClinicalTrials.gov

6. A Study of HLD-0117 in Patients With Metastatic Breast Cancer

   Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas

   Locations

   6 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07524855 on ClinicalTrials.gov

7. CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

   This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple Human Epiderm…

   Stage

   Phase 1

   Ages

   18 to 99

   Site

   The University of Texas Health Science Center at San Antonio, San Antonio, Texas

   Locations

   7 in total

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT05029999 on ClinicalTrials.gov

8. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

   This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer age…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START - San Antonio, San Antonio, Texas

   Locations

   8 in total

   Run by

   Olema Pharmaceuticals, Inc.

   See if you can join NCT06784193 on ClinicalTrials.gov